Trials / Completed
CompletedNCT03723252
Dapagliflozin Efficacy and Action in NASH
Efficacy and Safety of Dapagliflozin in Non-alcoholic Steatohepatitis: a Multicentre, Randomized, Placebo-controlled Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies and metabolic risk factors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin | Participants will receive dapagliflozin 10mg po qd |
| DRUG | Placebo | Participants will receive placebo po qd |
Timeline
- Start date
- 2019-03-20
- Primary completion
- 2024-03-22
- Completion
- 2024-03-28
- First posted
- 2018-10-29
- Last updated
- 2024-03-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03723252. Inclusion in this directory is not an endorsement.